RxDoctor Payments DataLook up a doctor →

Thomas Mueller, MD

Urology · Linwood, NJNPI 1003029836

Payments from drug & device makers

$1,194,416in general payments, 2019–2025

Across 1,014 payments — averaging $1177.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$690K
  • Neotract Inc.$262K
  • Calyxo, Inc.$139K
  • Angiodynamics, Inc.$51K
  • Procept Biorobotics Corporation$43K
  • SRS Medical Systems, Inc.$4K
  • plus $5K from 34 others

What the payments were for

  • Consulting fees$257,15424%
  • Speaking & faculty fees$668,13163%
  • Travel & lodging$70,8277%
  • Food & beverage$21,3292%
  • Education$4250%
  • Other$51,0005%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,194,416 in reported general payments places this provider in the 95th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$637,029
Medicare patients
911
Services billed
6,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron221$171,342
GemtesaVibegron80$71,494
Tamsulosin Hcl856$13,118
XyostedTestosterone Enanthate17$12,579
Mirabegron ErMirabegron19$10,284
Fesoterodine Fumarate ErFesoterodine Fumarate57$5,439
PremarinEstrogens, Conjugated11$5,053
Potassium Citrate ErPotassium Citrate66$4,971
Tadalafil64$4,342
Silodosin58$3,903
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst79$2,853
Oxybutynin Chloride137$2,742
Cefdinir148$2,282
Finasteride103$2,266
Testosterone12$1,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$747$171,342221 claims
Sumitomo Pharma America, Inc.Gemtesa$18$71,49480 claims
Antares Pharma, Inc.Xyosted$128$12,57917 claims
PfizerPremarin$68$5,05311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 401 urology providers in New Jersey.

Other urology in Linwood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →